You are here

Trends Pharmacol Sci DOI:10.1016/j.tips.2013.11.007

Genomic insights into WNT/β-catenin signaling.

Publication TypeJournal Article
Year of Publication2014
AuthorsRosenbluh, J, Wang, X, Hahn, WC
JournalTrends Pharmacol Sci
Volume35
Issue2
Pages103-9
Date Published2014 Feb
ISSN1873-3735
KeywordsAnimals, beta Catenin, Humans, Wnt Proteins, Wnt Signaling Pathway
Abstract

The canonical WNT pathway regulates the stability of the proto-oncogene β-catenin and is aberrantly activated in many cancer types. Studies in a wide range of experimental models confirm that β-catenin activity is required for tumor initiation in cancers where this pathway is deregulated. However, to date this pathway has proven to be challenging to target therapeutically. Moreover, several lines of evidence suggest that other components and regulators of β-catenin exist. Here we will describe recent structural and functional studies describing genomic alterations and new regulators of β-catenin that lead to aberrant activation of the WNT/β-catenin pathway. These findings provide new insights into the biology of WNT/β-catenin signaling and suggest potential therapeutic opportunities.

URLhttp://linkinghub.elsevier.com/retrieve/pii/S0165-6147(13)00227-7
DOI10.1016/j.tips.2013.11.007
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/24365576?dopt=Abstract

Alternate JournalTrends Pharmacol. Sci.
PubMed ID24365576
PubMed Central IDPMC3917662
Grant ListR01 CA140545 / CA / NCI NIH HHS / United States
U01 CA176058 / CA / NCI NIH HHS / United States